Therefore, we performed a systematic review and meta-analysis to assess the efficacy and safety of a combination of an SGLT2 inhibitor and a DPP4 inhibitor in patients with suboptimally controlled type 2 diabetes. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.